Skip to main content Skip to main navigation menu Skip to site footer

Low tumor-infiltrating lymphocytes (TIL) and high platelet lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR), and mean platelet volume (MPV) as a risk factor of metastasis in triple-negative breast cancer (TNBC)

  • Putu Bagus Anggaraditya ,
  • I Gede Budhi Setiawan ,
  • Putu Anda Tusta Adiputra ,

Abstract

Introduction: Triple Negative Breast Cancer (TNBC) is a subtype of breast cancer that is more aggressive and has a poor prognosis associated with an increased risk of metastasis. Cancer cells are known to trigger an inflammatory process which in turn causes tissue and vascular invasion, leading to changes in the levels of several hematological components. Unfortunately, research regarding various biomarkers in TNBC metastasis is still limited and argumentative. This study aims to determine the role of immune system-derived indices as biomarkers of metastasis in TNBC.

Method: This is a case-control study to examine the relationship between tumor-infiltrating lymphocyte (TIL), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) on metastasis in patients with TNBC subtype breast cancer. This research took place at the Medical Records Installation at RSUP Prof. DR. I.G.N.G Ngoerah Denpasar from August 2021 – April 2022. Research subjects were breast cancer patients with TNBC subtypes with metastases and without metastases who were registered in the Surgical Oncology Division in 2016-2021. All data analysis used SPSS for Windows version 23.0 with the p-value considered significant if p<0.05.

Results: A total of 100 research subjects were divided into metastatic (44 patients) and non-metastatic (56 patients) groups with a mean age of 52.97 ± 12.67 and 51.98 ± 10.86 years, respectively. Bivariate analysis showed a significant relationship between TIL (OR 0.163; IK95% 0.067 – 0.399; p=0.000), NLR (OR 3.644; IK95% 1.585 – 8.375; p=0.002), PLR (OR 9.755; IK95% 3.872 – 24.580; p=0.000), MPV (OR 9.500; 95% CI 6.512 – 58.393; p=0.000) on the incidence of metastasis. Multivariate analysis showed a significant relationship between the NLR and MPV variables (p<0.05).

Conclusion: Patients with metastases had significantly higher NLR and MPV values and significantly increased risk of metastasis in TNBC

References

  1. Santonja A, Sánchez-Muñoz A, Lluch A, Chica-Parrado MR, Albanell J, Chacón JI, et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018;9(41):26406–16. Available from: https://pubmed.ncbi.nlm.nih.gov/29899867
  2. Xia W-K, Liu Z-L, Shen D, Lin Q-F, Su J, Mao W-D. Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma. World J Surg Oncol. 2016;14:127. Available from: https://pubmed.ncbi.nlm.nih.gov/27125872
  3. De Giorgi U, Mego M, Scarpi E, Giordano A, Giuliano M, Valero V, et al. Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. Ther Adv Med Oncol. 2019;11:1758835919866065–1758835919866065. Available from: https://pubmed.ncbi.nlm.nih.gov/31452692
  4. Savas P, Loi S. Metastatic Breast Cancer: TIL it is Too Late. Clinical Cancer Research. 2020;26(3):526–8. Available from: http://dx.doi.org/10.1158/1078-0432.ccr-19-3490
  5. Zhu Y, Si W, Sun Q, Qin B, Zhao W, Yang J. Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer. Oncotarget. 2017;8(1):1023–30. Available from: https://pubmed.ncbi.nlm.nih.gov/27906679
  6. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013/03/31. 2013;16(1):55–9. Available from: https://pubmed.ncbi.nlm.nih.gov/23593082
  7. Jia W, Wu J, Jia H, Yang Y, Zhang X, Chen K, et al. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients. PLoS One. 2015;10(11):e0143061–e0143061. Available from: https://pubmed.ncbi.nlm.nih.gov/26580962
  8. Welch DR, Hurst DR. Defining the Hallmarks of Metastasis. Cancer Res. 2019/05/03. 2019;79(12):3011–27. Available from: https://pubmed.ncbi.nlm.nih.gov/31053634
  9. Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, et al. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913–24. Available from: https://pubmed.ncbi.nlm.nih.gov/27765921
  10. Indiralia A, Rahniayu A, Mustokoweni S. Perbedaan Ekspresi Foxp3+ dan Cd8+ Tumor Infiltrating Lymphocytes Karsinoma Payudara pada Berbagai Stadium T. Indonesian Journal of Cancer. 2018;12(1):7. Available from: http://dx.doi.org/10.33371/ijoc.v12i1.549
  11. Sejati IW, Manuaba IBTW, Tusta PA, Setiawan GB. Relationship between platelet-lymphocyte ratio and tumour infiltrating lymphocyte on metastatic in breast cancer patient. Int J Res Med Sci. 2019;7(6):2045. Available from: http://dx.doi.org/10.18203/2320-6012.ijrms20192153
  12. Stegner D, Dütting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res. 2014;133:S149–57. Available from: http://dx.doi.org/10.1016/s0049-3848(14)50025-4
  13. Takagi S, Takemoto A, Takami M, Oh-Hara T, Fujita N. Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis. Cancer Sci. 2014/07/28. 2014;105(8):983–8. Available from: https://pubmed.ncbi.nlm.nih.gov/24974736
  14. Ulas A, Kos T, Avci N, Cubukcu E, Olmez OF, Bulut N, et al. Patients with HER2-positive Early Breast Cancer Receiving Adjuvant Trastuzumab: Clinicopathological Features, Efficacy, and Factors Affecting Survival. Asian Pacific Journal of Cancer Prevention. 2015;16(4):1643–9. Available from: http://dx.doi.org/10.7314/apjcp.2015.16.4.1643
  15. Zhang F, Chen Z, Wang P, Hu X, Gao Y, He J. Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients. Tumour Biol. 2016/01/16. 2016;37(7):9323–31. Available from: https://pubmed.ncbi.nlm.nih.gov/26779631
  16. Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. Tohoku J Exp Med. 2015;236(4):297–304. Available from: http://dx.doi.org/10.1620/tjem.236.297
  17. Wiranata S, Anjani IAW, Saputra IPGS, Sadvika IGAS, Prabawa IPY, Supadmanaba IG, et al. Pretreatment neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio as a stage determination in breast cancer. Open Access Maced J Med Sci. 2020;8(B):1058–63.
  18. Onagi H, Horimoto Y, Sakaguchi A, Ikarashi D, Yanagisawa N, Nakayama T, et al. High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs. Breast Cancer Res. 2022;24(1):67. Available from: https://pubmed.ncbi.nlm.nih.gov/36217150
  19. Loi S, Adams S, Schmid P, Cortés J, Cescon DW, Winer EP, et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. Annals of Oncology. 2017;28:v608. Available from: http://dx.doi.org/10.1093/annonc/mdx440.005
  20. Caliskan B, Korkmaz AN. Can Neutrophil/Lymphocyte Ratio be a Predictor for Bone Metastases of Solid Tumors? World J Nucl Med. 2016;15(3):196–9. Available from: https://pubmed.ncbi.nlm.nih.gov/27651741
  21. Gago-Dominguez M, Matabuena M, Redondo CM, Patel SP, Carracedo A, Ponte SM, et al. Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions. Sci Rep. 2020;10(1):13203. Available from: https://pubmed.ncbi.nlm.nih.gov/32764699
  22. Orditura M, Galizia G, Diana A, Saccone C, Cobellis L, Ventriglia J, et al. Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. ESMO Open. 2016;1(2):e000038–e000038. Available from: https://pubmed.ncbi.nlm.nih.gov/27843594
  23. Moldoveanu D, Pravongviengkham V, Best G, Martínez C, Hijal T, Meguerditchian AN, et al. Dynamic Neutrophil-to-Lymphocyte Ratio: A Novel Prognosis Measure for Triple-Negative Breast Cancer. Ann Surg Oncol. 2020;27(10):4028–34. Available from: http://dx.doi.org/10.1245/s10434-020-08302-2
  24. de la Cruz-Ku G, Chambergo-Michilot D, Torres-Roman JS, Rebaza P, Pinto J, Araujo J, et al. Neutrophil-to-lymphocyte ratio predicts early mortality in females with metastatic triple-negative breast cancer. PLoS One. 2020;15(12):e0243447–e0243447. Available from: https://pubmed.ncbi.nlm.nih.gov/33284847
  25. Li M-M, Yue C-X, Fu S, Zhang X, Zhao C-J, Wang R-T. Platelet Volume Is Reduced In Metastasing Breast Cancer: Blood Profiles Reveal Significant Shifts. Cancer Manag Res. 2019;11:9067–72. Available from: https://pubmed.ncbi.nlm.nih.gov/31695497
  26. Aksoy S, Kilickap S, Hayran M, Harputluoglu H, Koca E, Dede DS, et al. Platelet size has diagnostic predictive value for bone marrow metastasis in patients with solid tumors. Int J Lab Hematol. 2008;30(3):214–9. Available from: http://dx.doi.org/10.1111/j.1751-553x.2007.00947.x
  27. Gu M, Zhai Z, Huang L, Zheng W, Zhou Y, Zhu R, et al. Pre-treatment mean platelet volume associates with worse clinicopathologic features and prognosis of patients with invasive breast cancer. Breast Cancer. 2015;23(5):752–60. Available from: http://dx.doi.org/10.1007/s12282-015-0635-6
  28. Hartono B, Pontoh VS, Merung MA. Penilaian jumlah neutrofil, limfosit dan trombosit, kadar protein reaktif C, kadar albumin, rasio neutrofil limfosit, serta rasio trombosit limfosit sebelum dan setelah terapi pada penderita karsinoma payudara. JURNAL BIOMEDIK (JBM). 2015;7(3). Available from: http://dx.doi.org/10.35790/jbm.7.3.2015.9487

How to Cite

Anggaraditya, P. B., I Gede Budhi Setiawan, & Adiputra, P. A. T. . (2024). Low tumor-infiltrating lymphocytes (TIL) and high platelet lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR), and mean platelet volume (MPV) as a risk factor of metastasis in triple-negative breast cancer (TNBC). Bali Medical Journal, 13(1), 760–767. https://doi.org/10.15562/bmj.v13i1.5198

HTML
6

Total
4

Share

Search Panel

Putu Bagus Anggaraditya
Google Scholar
Pubmed
BMJ Journal


I Gede Budhi Setiawan
Google Scholar
Pubmed
BMJ Journal


Putu Anda Tusta Adiputra
Google Scholar
Pubmed
BMJ Journal